Fasting blood sugar of 217 mg/dL (12.1 mmol/L) and an HbA1c of 8.8% (73 mmol/mol) indicate persistently poor glycaemic control and require prompt clinical attention. These results sit well above NICE-recommended targets for type 2 diabetes management and suggest that current treatment — whether lifestyle measures, medication, or both — needs review and likely intensification. This article explains what these values mean in the context of UK clinical practice, how they are assessed under NHS and NICE guidelines, which treatment options may be considered, and when to seek urgent medical advice.

What Do a Fasting Plasma Glucose of 217 mg/dL and HbA1c of 8.8% Mean?

A fasting plasma glucose of 12.1 mmol/L and HbA1c of 73 mmol/mol both exceed NHS diagnostic thresholds for diabetes and together indicate sustained, poorly controlled hyperglycaemia with increased risk of long-term complications.

A fasting plasma glucose (FPG) of 217 mg/dL (approximately 12.1 mmol/L in UK units) is significantly above the normal fasting range of 4.0–5.4 mmol/L. In the context of diabetes management, this level indicates that blood glucose is poorly controlled in the fasting state — meaning the body is unable to regulate glucose effectively even without the influence of recent food intake.

An HbA1c of 8.8% (approximately 73 mmol/mol in IFCC units used by NHS laboratories) reflects the average blood glucose level over the preceding two to three months. This is well above the NICE-recommended target of 48 mmol/mol (6.5%) for people managed by lifestyle or a single non-hypoglycaemic drug such as metformin, and substantially above the 58 mmol/mol (7.5%) threshold at which NICE typically recommends considering treatment intensification.

Importantly, in the UK these values meet the diagnostic thresholds for diabetes: an HbA1c of ≥48 mmol/mol or a fasting plasma glucose of ≥7.0 mmol/L. If a person has no symptoms of diabetes, a repeat confirmatory test is required before a diagnosis is made. If symptoms are present (such as thirst, frequent urination, or unexplained weight loss), a single abnormal result may be sufficient. Interpretation should always be carried out by a qualified healthcare professional in the context of the individual's full medical history, current medications, and lifestyle factors.

Together, these two results paint a consistent picture: blood glucose has been persistently elevated over a prolonged period. This level of glycaemic control is associated with an increased risk of both short-term symptoms (such as fatigue, thirst, and frequent urination) and long-term complications, including:

Not sure if this is normal? Chat with one of our pharmacists →

• Cardiovascular disease

• Diabetic nephropathy (kidney damage)

• Retinopathy (eye damage)

• Peripheral neuropathy (nerve damage)

HbA1c targets should be individualised — your GP or diabetes team will agree a personal target with you based on your treatment, age, risk of hypoglycaemia, and other health conditions.

How These Results Are Assessed Under NHS and NICE Guidelines

Under NICE NG28, an HbA1c of 73 mmol/mol (8.8%) represents suboptimal glycaemic control and typically prompts a structured clinical review of medication, lifestyle, renal function, and cardiovascular risk.

Under NICE guideline NG28 (Type 2 Diabetes in Adults: Management), an HbA1c of 73 mmol/mol (8.8%) in a person already diagnosed with type 2 diabetes represents suboptimal glycaemic control and would typically prompt a structured clinical review. NICE recommends that HbA1c is measured every three to six months when treatment is being adjusted, and at least annually once stable.

The NHS uses HbA1c as the primary marker for assessing long-term diabetes control. An HbA1c above 58 mmol/mol (7.5%) is generally the threshold at which NICE recommends considering treatment intensification; 73 mmol/mol (8.8%) is notably above this. HbA1c targets should be individualised — for example, less stringent targets may be appropriate for older or frail adults, or those at higher risk of hypoglycaemia. A GP or diabetes specialist would typically review:

• Current medication regimen and adherence

• Dietary habits and physical activity levels

• Presence of complications or comorbidities (including cardiovascular disease, heart failure, or chronic kidney disease)

• Renal function (eGFR and urine albumin-to-creatinine ratio), as this influences medication choices

• Cardiovascular risk, which may influence the choice of glucose-lowering agent

A fasting plasma glucose of 12.1 mmol/L would also be flagged as clinically significant. While a single reading can be influenced by illness, stress, or missed medication, when combined with a high HbA1c, it strongly suggests a pattern of sustained hyperglycaemia rather than an isolated episode.

NICE also recommends that individuals with poorly controlled diabetes are offered structured education programmes such as the Diabetes Education and Self Management for Ongoing and Newly Diagnosed (DESMOND) programme, which supports patients in understanding and managing their condition more effectively. A referral to a diabetes specialist nurse or dietitian may also be appropriate at this stage.

Treatment Options for Poorly Controlled Type 2 Diabetes

NICE recommends a stepwise approach: metformin is first-line for most people, with SGLT-2 inhibitors prioritised in those with cardiovascular disease or CKD; insulin may be considered if HbA1c remains elevated despite dual or triple therapy.

When blood glucose and HbA1c remain elevated despite initial treatment, NICE guideline NG28 recommends a stepwise approach to intensifying therapy. The choice of medication depends on individual factors including renal function, cardiovascular risk, body weight, comorbidities, and patient preference. All prescribing decisions should be made by a GP or diabetes specialist.

First-line treatment for most people with type 2 diabetes is metformin, which works by reducing hepatic glucose production and improving insulin sensitivity. Metformin should be reviewed if eGFR falls below 45 mL/min/1.73 m² (dose reduction) and is contraindicated if eGFR is below 30 mL/min/1.73 m².

SGLT-2 inhibitors (e.g., empagliflozin, dapagliflozin, canagliflozin) occupy an increasingly important role in UK practice. Per NICE technology appraisals and NG28, they may be initiated first-line alongside or instead of metformin in people with established atherosclerotic cardiovascular disease (ASCVD), high cardiovascular risk, heart failure, or chronic kidney disease (CKD), irrespective of baseline HbA1c, because of their proven organ-protective benefits. They reduce glucose reabsorption in the kidneys and have cardiovascular and renal protective effects. Key safety points include an increased risk of genital mycotic infections, and a rare risk of diabetic ketoacidosis (DKA) — including euglycaemic DKA. Patients taking SGLT-2 inhibitors should follow sick-day rules: temporarily stopping the medication during acute illness, surgery, or prolonged fasting, and seeking medical advice promptly. Initiation thresholds vary by agent and indication; your prescriber will check your renal function before starting.

If HbA1c remains above target on metformin alone (in those without the above high-risk conditions), NICE-recommended second-line options include:

• DPP-4 inhibitors (e.g., sitagliptin, alogliptin) — generally well tolerated with a low risk of hypoglycaemia

• Sulfonylureas (e.g., gliclazide) — stimulate insulin release from the pancreas; effective but carry a risk of hypoglycaemia and weight gain; patients should receive hypoglycaemia education when starting

• Pioglitazone — may be considered in certain combinations per NICE, though it is not suitable for everyone (e.g., those with heart failure or bladder cancer history)

• SGLT-2 inhibitors — as above, also used as second-line agents

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) promote insulin secretion, suppress glucagon, and support weight loss. In the UK, NICE typically recommends them in more specific circumstances — often as part of triple therapy, or where insulin would otherwise be considered, and usually with BMI criteria (e.g., BMI ≥35 kg/m², or lower in people of South Asian or other high-risk ethnic backgrounds). Continuation is generally recommended only if the person achieves a reduction in HbA1c of at least 11 mmol/mol and a weight loss of at least 3% of initial body weight at around six months. Your diabetes team will advise whether a GLP-1 receptor agonist is appropriate for you.

If HbA1c remains significantly elevated despite dual or triple oral therapy, insulin therapy may be considered. Basal insulin (long-acting) is often introduced first, with doses titrated carefully to avoid hypoglycaemia. Patients starting insulin should receive structured education on hypoglycaemia recognition and management.

Patients should never adjust doses independently without professional guidance, as this carries risks of both hypoglycaemia and further deterioration in control. If you experience suspected side effects from any diabetes medication, you can report these to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk. For detailed prescribing information, refer to the BNF or the relevant Summary of Product Characteristics (SmPC).

Lifestyle Changes That Can Help Lower Blood Sugar and HbA1c

Dietary changes, at least 150 minutes of moderate aerobic activity weekly, and weight management can meaningfully reduce HbA1c and remain a cornerstone of diabetes management at every treatment stage.

Lifestyle modification remains a cornerstone of diabetes management at every stage. Evidence suggests that meaningful changes in diet and physical activity can reduce HbA1c by around 0.3–1% (3–11 mmol/mol) in many individuals, with larger reductions possible in those achieving substantial weight loss. Even modest improvements can have a meaningful impact on glycaemic control.

Dietary changes are particularly important. A diet lower in refined carbohydrates and added sugars helps reduce postprandial glucose spikes. Practical steps include:

• Choosing wholegrain versions of bread, rice, and pasta

• Reducing intake of sugary drinks, sweets, and processed foods

• Increasing vegetables, legumes, and lean proteins

• Eating regular, balanced meals to avoid large fluctuations in blood glucose

Low-carbohydrate diets have shown promising results in improving HbA1c and reducing medication requirements in some people with type 2 diabetes. However, these should be undertaken with support from a dietitian and with close involvement of your diabetes team, particularly if you are taking insulin or sulfonylureas, as significant dietary changes can increase the risk of hypoglycaemia and may require prompt medication adjustment.

Physical activity improves insulin sensitivity and helps muscles use glucose more effectively. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week, alongside resistance exercises on two or more days. Even short bouts of walking after meals can meaningfully reduce postprandial glucose levels.

Weight management is also highly relevant. The NHS Type 2 Diabetes Path to Remission Programme (also known as the NHS Low Calorie Diet Programme), which is based on evidence from the DiRECT trial, has demonstrated that significant weight loss can lead to remission of type 2 diabetes in some individuals. Referral to this programme may be appropriate for eligible patients — speak to your GP or diabetes team for further information.

Smoking cessation and reducing alcohol intake are additional lifestyle factors that support better glycaemic control and overall cardiovascular health. Diabetes UK provides practical resources on dietary approaches and lifestyle management.

When to Seek Urgent Medical Advice or GP Review

Call 999 immediately if symptoms of DKA, hyperosmolar hyperglycaemic state, or severe hypoglycaemia occur; contact your GP promptly for persistent readings above 15 mmol/L, worsening symptoms, or concerns about medication.

Whilst an HbA1c of 8.8% and a fasting plasma glucose of 12.1 mmol/L require prompt clinical review, they do not in themselves constitute a medical emergency. However, there are specific circumstances in which urgent medical attention should be sought without delay.

Contact 999 or go to A&E immediately if you or someone else experiences:

• Symptoms of diabetic ketoacidosis (DKA): rapid or laboured breathing, fruity-smelling breath, vomiting, confusion, or extreme fatigue — though DKA is more common in type 1 diabetes, it can occur in type 2, and rarely in people taking SGLT-2 inhibitors even when blood glucose is not markedly elevated (euglycaemic DKA)

• Hyperosmolar hyperglycaemic state (HHS): extreme thirst, very high blood glucose (often above 30 mmol/L), confusion, or drowsiness — this is a serious complication more specific to type 2 diabetes

• Severe hypoglycaemia: loss of consciousness or inability to swallow safely

If you are unwell and have persistently high blood glucose (above 13.9 mmol/L), check blood ketones if you have a ketone meter. Seek urgent medical attention the same day (via your GP, NHS 111, or A&E as appropriate) if blood ketones are 3.0 mmol/L or above, urine ketones are ++ or higher, or if you are vomiting, unable to keep fluids down, or becoming confused. These may be signs of DKA or HHS.

Contact your GP or diabetes team promptly (within a few days) if you experience:

• Persistent blood glucose readings above 15 mmol/L

• Symptoms of infection (which can dramatically worsen glucose control)

• Unexplained weight loss, excessive thirst, or frequent urination that has worsened recently

• Concerns about your current medication or side effects

Regular scheduled reviews are equally important. NICE recommends that people with type 2 diabetes have an annual review covering HbA1c, blood pressure, cholesterol, kidney function, foot examination, and eye screening. If your results have not been reviewed recently, booking an appointment with your GP or practice nurse is an important first step.

Monitoring and Target Levels Recommended in the UK

NICE recommends an HbA1c target of 48 mmol/mol (6.5%) for those on lifestyle or single non-hypoglycaemic therapy, and 53 mmol/mol (7.0%) for those on hypoglycaemia-risk medications; targets should be individualised by your healthcare team.

Effective diabetes management depends on regular, structured monitoring. In the UK, HbA1c is the primary tool for assessing long-term glycaemic control and is measured in mmol/mol under the IFCC standardisation used by NHS laboratories. Per NICE NG28, HbA1c should be checked every three to six months when treatment is being adjusted, and at least annually once stable.

NICE-recommended HbA1c targets for adults with type 2 diabetes are:

• 48 mmol/mol (6.5%) — for those managed by lifestyle alone or a single non-hypoglycaemic drug (e.g., metformin alone)

• 53 mmol/mol (7.0%) — for those on medications that carry a risk of hypoglycaemia (e.g., sulfonylureas or insulin)

These targets should be individualised in discussion with your healthcare team. Less stringent targets may be appropriate for older or frail adults, those with significant comorbidities, or those at higher risk of hypoglycaemia. An HbA1c of 73 mmol/mol (8.8%) is substantially above both thresholds and warrants active treatment review.

For self-monitoring of blood glucose (SMBG), not all people with type 2 diabetes are routinely advised to test at home — this depends on treatment type and individual circumstances. Those on insulin or at risk of hypoglycaemia are typically advised to monitor regularly. According to Diabetes UK, commonly used reference ranges are a fasting blood glucose of 4.0–7.0 mmol/L and a two-hour post-meal level of below 8.5 mmol/L, though individual targets should be agreed with your diabetes team. These targets differ in pregnancy and gestational diabetes — if you are pregnant or planning a pregnancy, discuss appropriate targets with your obstetric or diabetes team.

Beyond glucose monitoring, the NHS annual diabetes review also assesses:

• Blood pressure — targets are generally below 140/80 mmHg, or 130/80 mmHg in those with kidney, eye, or cerebrovascular disease, per NICE guidance; home and clinic readings may differ and targets should be individualised

• Cholesterol and cardiovascular risk

• Kidney function (eGFR and urine albumin-to-creatinine ratio)

• Foot and eye health

Keeping a record of your readings and bringing them to appointments helps your healthcare team tailor your management plan effectively. Diabetes UK provides further guidance on blood glucose targets and self-monitoring.

Frequently Asked Questions